1. Home
  2. COHN vs IGC Comparison

COHN vs IGC Comparison

Compare COHN & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Company Inc.

COHN

Cohen & Company Inc.

HOLD

Current Price

$17.00

Market Cap

34.2M

Sector

Finance

ML Signal

HOLD

Logo IGC Pharma Inc.

IGC

IGC Pharma Inc.

HOLD

Current Price

$0.30

Market Cap

31.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COHN
IGC
Founded
1999
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.2M
31.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
COHN
IGC
Price
$17.00
$0.30
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.13
AVG Volume (30 Days)
41.8K
933.9K
Earning Date
11-04-2025
11-17-2025
Dividend Yield
6.15%
N/A
EPS Growth
6.29
N/A
EPS
2.50
N/A
Revenue
$185,475,000.00
$1,106,000.00
Revenue This Year
N/A
$3.54
Revenue Next Year
N/A
$15.12
P/E Ratio
$6.51
N/A
Revenue Growth
107.11
N/A
52 Week Low
$6.10
$0.25
52 Week High
$20.70
$0.50

Technical Indicators

Market Signals
Indicator
COHN
IGC
Relative Strength Index (RSI) 53.30 39.57
Support Level $15.23 $0.29
Resistance Level $16.98 $0.36
Average True Range (ATR) 1.51 0.03
MACD -0.47 0.00
Stochastic Oscillator 32.36 25.36

Price Performance

Historical Comparison
COHN
IGC

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Share on Social Networks: